Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts E. Gabriela Chiorean, MD; Tanios S. Bekaii-Saab, MD; Mitesh Borad, MD; and Christopher Lieu, MD, discuss the evolving role of KRAS-targeted therapies in pancreatic cancer, including underlying biology, emerging clinical data, and real-world challenges in treatment selection and trial access.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret efficacy and safety data from recent and ongoing clinical trials of KRAS-targeted therapies for advanced PDAC
• Apply emerging clinical evidence, molecular profiling results, and patient-specific factors to guide the selection and sequencing of targeted therapies in advanced PDAC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Revolution Medicines.

Chair:

E. Gabriela Chiorean, MD

Professor of Medicine, University of Washington
School of Medicine
Clinical Director, Gastrointestinal Oncology
Professor, Fred Hutchinson Cancer Center
Seattle, WA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AADi, Abbvie, BMS, Fortvita, GSK, Merus, Pfizer, Purple, Regeneron, Takeda, Verastem; Grant/Research Funding: Affini-T, BioAtla, BMS, Erasca, Genentech, Janssen, Lonza, Revolution Medicines, Sanofi, Sapience

Faculty:

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel
Therapeutics for Cancer Research I
Chair, Division of Hematology and Medical Oncology
Mayo Clinic in Arizona
Phoenix, AZ

Disclosures: Research Funding (to institution): Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Seattle Genetics; Consulting (to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck, Merus, Pfizer, Revolution Medicines, Seattle Genetics, Servier; Consulting (to self): AbbVie, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Exact Sciences, Exelixis, Foundation Medicine, GSK, Illumina, Janssen, Kanaph, Natera, Sanofi, Sobi, Stemline, Takeda, Treos Bio, Xilio, Zai Lab; IDMC/DSMB: 1Globe, AstraZeneca, Exelixis, FibroGen, Merck/Eisai, PanCAN; Suzhou Kintor, The Valley Hospital; Scientific Advisory Board: Artiva, Immuneering, Imugene, Replimune, Sun Biopharma, Xilis; Royalties: UpToDate; Inventions/Patents: WO/2018/183488: Human PD1 Peptide Vaccines and Uses Thereof: licensed to Imugene; WO/2019/055687: Methods and Compositions for the Treatment of Cancer Cachexia: licensed to Recursion

Mitesh Borad, MD

Professor of Medicine
Co-Leader, Novel Therapeutics and Therapeutic
Modalities Program
Mayo Clinic Comprehensive Cancer Center
Phoenix, AZ

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Accession Therapeutics, Amplia, Breakthru Bio, Cardinal Health, Cedilla, Cogent, Compass Therapeutics, Diffusion Pharmaceuticals, Eisai, Elevar, Exelixis, George Clinical, Guardant, Imugene, IMVAX, Jazz Pharmaceuticals, Kalivir Immunotherapeutics, Karkinos, Khora, Kriya Therapeutics, Merck, Moderna, Orum Therapeutics, Processa, RayzeBio, Reignite Therapeutics, Revolution Medicines, Senti Biosciences, Servier, Tempus, Vionix, Zielbio, ZymeWorks; Research Funding (to institution): Agios, Alentis Therapeutics, Arvinas, AstraZeneca, Basilea, Biond, Cogent, Compass Therapeutics, Elevar, Elevation, H3 Biomedicines, Incyte, Medilink, Nuvectis, Pfizer, RayzeBio, Relay Therapeutics, Revolution Medicines, Sanofi, SeaGen, Tango Therapeutics; Stock Ownership: Abeona, ADC Therapeutics, Assertio, Homology

Christopher Lieu, MD

Professor of Medicine
Director, GI Medical Oncology
Associate Director for Clinical Research
University of Colorado Cancer Center
Aurora, CO

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient (paid to institution): Pfizer; Grant/Research Funding (paid to institution): Genentech, Sanofi

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on KRAS-targeted therapies, clinical trial strategies, and emerging treatment approaches in pancreatic cancer, go to https://www.gotoper.com/sogo26pdac-activity.

Release Date

May 1, 2026

Expiration Date

May 1, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.